May Zaw Thin

May Zaw Thin

Auto-generated profile, based on publicly available information

May Zaw Thin

Cancer Stem Cell Laboratory, Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Cancer Cell
Verified
Journal Article
Open access
ZSZachary Schug
Zachary Schug
Barrie PeckBarrie Peck
Barrie Peck
DJDylan T. Jones
Dylan T. Jones
QZQifeng Zhang
Qifeng Zhang
SGShaun Grosskurth
Shaun Grosskurth
EGEyal Gottlieb
Eyal Gottlieb
A functional genomics study revealed that the activity of acetyl-CoA synthetase 2 (ACSS2) contributes to cancer cell growth under low-oxygen and lipid-depleted conditions. Comparative metabolomics and lipidomics demonstrated that acetate is used as a nutritional source by cancer cells in an ACSS2-dependent manner, and supplied a significant fraction of the carbon within the fatty acid and phospholipid pools. ACSS2 expression is upregulated under metabolically stressed conditions and ACSS2 silencing reduced the growth of tumor xenografts. ACSS2 exhibits copy-number gain in human breast tumors, and ACSS2 expression correlates with disease progression. These results signify a critical role for acetate consumption in the production of lipid biomass within the harsh tumor microenvironment.

30 March 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SCSandra D. Castillo
Sandra D. Castillo
ETElena Tzouanacou
Elena Tzouanacou
MZMay Zaw-Thin
May Zaw-Thin
IBInma M. Berenjeno
Inma M. Berenjeno
VPVictoria E.R. Parker
Victoria E.R. Parker
BVBart Vanhaesebroeck
Bart Vanhaesebroeck
Mutant Pik3ca gives rise to venous malformations.

1 November 2013 in Cancer Cell
Verified
Journal Article
Open access
ECEsther Castellano
Esther Castellano
CSClare Sheridan
Clare Sheridan
MTMay Zaw Thin
May Zaw Thin
ENEmma Nye
Emma Nye
BSBradley Spencer-Dene
Bradley Spencer-Dene
JDJulian Downward
Julian Downward
RAS proteins directly activate PI3-kinases. Mice bearing a germline mutation in the RAS binding domain of the p110α subunit of PI3-kinse are resistant to the development of RAS-driven tumors. However, it is unknown whether interaction of RAS with PI3-kinase is required in established tumors. The need for RAS interaction with p110α in the maintenance of mutant Kras-driven lung tumors was explored using an inducible mouse model. In established tumors, removal of the ability of p110α to interact with RAS causes long-term tumor stasis and partial regression. This is a tumor cell-autonomous effect, which is improved significantly by combination with MEK inhibition. Total removal of p110α expression or activity has comparable effects, albeit with greater toxicities.

4 November 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
VWVictoria M.-Y. Wang
Victoria M.-Y. Wang
RFRute M. M. Ferreira
Rute M. M. Ferreira
JAJorge Almagro
Jorge Almagro
TETheodore Evan
Theodore Evan
NLNathalie Legrave
Nathalie Legrave
ABAxel Behrens
Axel Behrens

19 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JNJessica K. Nelson
Jessica K. Nelson
MTMay Zaw Thin
May Zaw Thin
TETheodore Evan
Theodore Evan
SHSteven Howell
Steven Howell
MWMary Wu
Mary Wu
ABAxel Behrens
Axel Behrens
Deubiquitylating enzymes (DUBs) play an essential role in targeted protein degradation and represent an emerging therapeutic paradigm in cancer. However, their therapeutic potential in pancreatic ductal adenocarcinoma (PDAC) has not been explored. Here, we develop a DUB discovery pipeline, combining activity-based proteomics with a loss-of-function genetic screen in patient-derived PDAC organoids and murine genetic models. This approach identifies USP25 as a master regulator of PDAC growth and maintenance. Genetic and pharmacological USP25 inhibition results in potent growth impairment in PDAC organoids, while normal pancreatic organoids are insensitive, and causes dramatic regression of patient-derived xenografts. Mechanistically, USP25 deubiquitinates and stabilizes the HIF-1α transcription factor. PDAC is characterized by a severely hypoxic microenvironment, and USP25 depletion abrogates HIF-1α transcriptional activity and impairs glycolysis, inducing PDAC cell death in the tumor hypoxic core. Thus, the USP25/HIF-1α axis is an essential mechanism of metabolic reprogramming and survival in PDAC, which can be therapeutically exploited.

27 November 2020 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
HMHendrik A. Messal
Hendrik A. Messal
JAJorge Almagro
Jorge Almagro
MTMay Zaw Thin
May Zaw Thin
ATAntonio Tedeschi
Antonio Tedeschi
ACAlessandro Ciccarelli
Alessandro Ciccarelli
ABAxel Behrens
Axel Behrens